Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18884208 | 0.80 | EPHX2 (0.73) | EPHX2EPHX1KMT2ASMN1; SMN2FAAH | |
| SCHEMBL3069160 | 0.80 | EPHX2 (1.00) | EPHX2EPHX1JAK2ALDH1A1LMNA | |
| SCHEMBL6531345 | 0.80 | ALDH1A1 (0.46) | EPHX2EPHX1ALDH1A1 | |
| SCHEMBL1694443 | 0.78 | EPHX2 (0.70) | EPHX2EPHX1KMT2ASMN1; SMN2FAAH | |
| SCHEMBL30500314 | 0.78 | EPHX2 (0.70) | EPHX2EPHX1KMT2ASMN1; SMN2FAAH | |
| SCHEMBL4431734 | 0.76 | EPHX2 (0.67) | EPHX2EPHX1KMT2ASMN1; SMN2FAAH | |
| SCHEMBL8392931 | 0.76 | EPHX2 (0.67) | EPHX2EPHX1KMT2ASMN1; SMN2FAAH | |
| SCHEMBL1149916 | 0.76 | EPHX2 (0.67) | EPHX2EPHX1KMT2ASMN1; SMN2FAAH | |
| SCHEMBL19757636 | 0.76 | EPHX1 (0.68) | EPHX2EPHX1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL133014 | 0.76 | EPHX1 (0.68) | EPHX2EPHX1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-52010284-A | — | — | None | — | — | JP | disclosed |
| JP-52010283-A | — | — | None | — | — | JP | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| CN-1498217-A | Heterocyclic compounds for aging-related and diabetic vascular complications | ������˹ҩƷ��˾ | 2004-05-19 | — | — | CN | disclosed |
| US-4789674-A | ALZHEIMER'S DISEASE, MEMORY, DEMENTIA | CIBA-GEIGY CORPORATION (US) | 1988-12-06 | — | — | US | disclosed |
| US-4758575-A | Bi-2H-pyrroli(di)nediones | CIBA-GEIGY CORPORATION (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0192255-A2 | Bis-2H-pyrrolidine diones | CIBA-GEIGY AG (CH) | 1986-08-27 | — | — | EP | disclosed |
| JP-S5210284-A | PROCESS FOR PREPARING PIPERAZINE DERIVATIVES | TANABE SEIYAKU CO LTD | 1977-01-26 | — | — | JP | disclosed |
| JP-S5210283-A | A PROCESS FOR PREPARING PIPERAZINE DERIVATIVES | TANABE SEIYAKU CO LTD | 1977-01-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | EPHX2 2282/4885EPHX1 3653/4885KMT2A 1865/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | EPHX2 2733/4885EPHX1 2426/4885KMT2A 2063/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | EPHX2 2282/4885EPHX1 3653/4885KMT2A 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.